Cardiac biomarkers in heart failure

Related Experiment Video

Updated: May 3, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K

Michael E Liquori1, Robert H Christenson2, Paul O Collinson3

  • 1University of Maryland School of Medicine, Department of Internal Medicine, 22 S. Greene St, Baltimore, MD 21201, USA.

Clinical Biochemistry
|February 18, 2014
PubMed

Insights

Blood biomarkers are crucial for managing heart failure, aiding in early diagnosis, prognosis, and treatment. As heart failure prevalence rises globally, these markers will become increasingly vital for patient care.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Clinical Diagnostics

Background:

  • Heart failure is a global health concern with increasing prevalence due to aging populations.
  • The condition signifies the heart's inability to meet the body's circulatory demands.
  • Advancements in cardiac therapies highlight the growing importance of biomarkers in patient management.

Purpose of the Study:

  • To review clinical research on blood-based biomarkers for heart failure.
  • To focus on currently available biomarkers for clinical measurement.
  • To explore current and potential applications in managing heart failure patients.

Main Methods:

  • Systematic review of clinical research on heart failure biomarkers.
  • Analysis of biomarkers for diagnosis, prognosis, and therapeutic guidance.
  • Evaluation of biomarkers based on clinical availability and application.

Main Results:

  • Heart failure biomarkers are associated with diverse biologic pathways: inflammation, remodeling, strain, neurohormonal activation, metabolism, and cardiac myocyte injury.
  • The review discusses the clinical characteristics and applications of various heart failure biomarkers.
  • Specific biomarkers are linked to different pathophysiological processes in heart failure.

Conclusions:

  • Heart failure incidence and prevalence are expected to increase with aging populations and improved cardiovascular disease interventions.
  • Blood biomarkers will play a progressively significant role in the future management of heart failure.
  • Biomarkers are essential for early diagnosis, therapeutic monitoring, and overall patient management in heart failure.
Abstract

Keywords:
BiomarkersCardiacHeart failureNatriuretic peptideTroponin

More Related Videos

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.1K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.7K
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
787